Compare

Medios AG/€ILM1

1D1W1M3M6MYTD1Y5YMAX

About Medios AG

Medios AG, headquartered in Berlin, Germany, specializes in the supply and manufacturing of specialty pharmaceutical products, focusing on treatments for chronic and rare diseases. The company operates through two primary segments: Pharmaceutical Supply, offering a portfolio of approximately 1,000 specialty pharma drugs across therapeutic areas such as oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia; and Patient-Specific Therapies, producing individualized medications, including cytostatic infusions, antibody therapies, virostatic and antibiotic medications, and parenteral nutrition solutions, with around 400,000 preparations completed in fiscal year 2023. Founded in 2016, Medios AG has expanded its geographic footprint to include operations in Germany, the Netherlands, Belgium, and Spain. The company's strategic positioning emphasizes individualized medicine, collaborating with pharmacies, specialist practices, and pharmaceutical companies to make innovative therapies widely accessible.
Ticker
€ILM1
Sector
Health
Primary listing
XETRA
Employees
989
Headquarters
Berlin, Germany
Website
www.medios.ag

Medios AG Metrics

BasicAdvanced
€278M
34.32
€0.33
-
-

What the Analysts think about Medios AG

Analyst ratings (Buy, Hold, Sell) for Medios AG stock.
Analyst projections of the future price of Medios AG stock.

Bulls say / Bears say

Revenue rose 6.7% in the first nine months of 2026, with growth in all operating segments. This shows the business is still expanding despite a difficult market. (Deutsche Börse)
Medios is shifting investment towards compounding, which it says has structurally higher margins than its supply business. Its 2031 plan targets €3.1 billion of revenue and €170 million of adjusted EBITDA, offering scope for earnings to grow faster than sales if delivered. (EQS News)
Medios says its efficiency programme had generated €2.7 million in savings by September and is targeting €5 million for 2026. The patient-specific therapies margin improved quarter on quarter for a third consecutive period, suggesting some operational measures are beginning to help. (Deutsche Börse)
Revenue growth is not yet translating into stronger profits: nine-month EBITDA pre fell to €66.7 million from €70.4 million, while its margin declined to 4.1% from 4.6%. Operating cash flow halved to €26.2 million, and free cash flow before acquisitions fell to €15.9 million from €47.9 million. (Deutsche Börse)
Price declines in higher-margin supply products and drug-price regulation are weighing on earnings, and the company expects a further €1.2 million fourth-quarter EBITDA pre burden from Germany’s revised Hilfstaxe. Medios now expects full-year EBITDA pre at the lower end of its €88–92 million forecast range. (Deutsche Börse)
The 2031 earnings ambition depends on expanding compounding and selective acquisitions, so it will take successful execution to achieve. Caelo is still being integrated, and Medios expects its €3.4 million of annual synergies only from 2028/29 onwards. (EQS News, Deutsche Börse)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2026.

Medios AG Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Medios AG Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.